Cogent Biosciences, Inc. income statement

In fiscal 2020, Cogent Biosciences, Inc. reported revenue of $7.9m, down 65.0% on the year before, operating income of −$82.2m (a -1044.3% margin) and net income of −$74.8m, or −$16.17 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cogent Biosciences, Inc.: income statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Revenue	8	10	22	8
Research and development	30	38	44	26
General and administrative	5	7	11	17
Operating income	−26	−36	−32	−82
Net income	−25	−35	−32	−75
Diluted EPS	−$2.51	−$1.39	−$4.18	−$16.17
Diluted shares (average)	3m	6m	8m	11m
EBITDA	−25	−35	−31	−81

US$ millions unless shown otherwise. Fiscal quarters.

Cogent Biosciences, Inc.: income statement, quarterly
Quarter	2019 Q1Mar 2019	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Revenue	3	3	1	15	7	1	0	0
Research and development	12	11	10	10	9	5	5	6
General and administrative	2	3	3	3	4	3	6	5
Operating income	−12	−11	−12	2	−6	−7	−57	−11
Net income	−12	−11	−12	2	−6	−7	−50	−11
Diluted EPS	−$1.56	−$1.36	−$1.56	$0.28	−$0.81	−$0.95	−$5.07	−$8.61
EBITDA	−12	−10	−12	3	−6	−7	−57	−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cogent Biosciences, Inc.